Anumana, an AI health technology company of nference, has acquired NeuTrace, a medical technology company advancing novel in-procedure AI applications for electrophysiology (EP).
The acquisition includes the NeuTrace EP Data Biome platform and a portfolio of AI-enabled EP software applications, which are currently under development.
Its parent organisation nference has obtained the rights to NeuTrace Data Biome platform, for use outside of the cardiovascular field.
Anumana said that the acquisition strengthens its position as a developer of AI medical software for cardiac EP, powered by nference’s nSights real-world evidence platform.
Anumana chief business officer David McMullin said: “Anumana is pioneering new ground in cardiology AI software solutions that span the entire patient journey.
“With its deep learning models detecting patterns too subtle for the human eye to see, from undiagnosed disease in routine ECGs to real-time EGM signals during critical EP procedures, Anumana is on a mission to improve patient care by unlocking the electrical language of the heart as never before.”
NeuTrace has a portfolio of EP applications currently under development, which can enhance procedure accuracy, reduce time, and improve patient safety and outcomes.
Covered by more than 35 pending and registered patents, NeuTrace’s EP Data Biome is a unique platform that enables in-procedure data integration and novel AI applications.
The platform can integrate a patient’s complete electronic medical record (EMR) with corresponding electrocardiograms (ECG), and cardiac electrograms (EGM).
The in-procedure EGM and ECG data feeds, combined with pre- and post-procedure ECG and EMR data records, will enable improved ECG-AI-based diagnosis.
NeuTrace president and chief operating officer Srijoy Mahapatra said: “We’ve been impressed by the complementary depth, breadth, and strength of the Anumana and nference teams and are excited by the transformative potential of the combined organizations.
“Combining the power of NeuTrace’s EP Data Biome with EMR and other data modalities of nference’s nSights platform has the potential to unlock game-changing AI applications in early cardiovascular disease detection, rhythm management, and EP procedure safety, efficacy, and effectiveness, for improved long-term outcomes.”
Earlier this year, Anumana entered into a strategic collaboration with Novartis to detect heart disease by leveraging a series of AI-powered software solutions.
